Today: 9 June 2026
Browse Category

NASDAQ:ARQT 30 December 2025 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares fell 5.3% to $28.29 Friday after an early surge, tracking a shift in rate expectations following a soft U.S. jobs report. Broader biotech indexes rose. Investors are watching for Arcutis’ next earnings on Feb. 24 and an FDA decision on ZORYVE for children by June 29. The Fed’s late-January meeting remains a key focus for traders.
9 January 2026
···
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis Biotherapeutics shares closed up 3.4% at $29.04 in the final trading session of the year. A Form 144 filing showed Chief Medical Officer Patrick Burnett plans to sell 1,697 shares after acquiring them through restricted stock vesting. U.S. stock markets are closed Thursday for New Year’s Day and reopen Friday. The stock’s move contrasted with a broader market pullback.
1 January 2026
·

Stock Market Today

  • Yamaha Motor (TSE:7272) Stock Valuation and Recent Performance Analysis
    June 9, 2026, 11:53 AM EDT. Yamaha Motor's (TSE:7272) shares rose 10.3% over the past month, reflecting strong momentum with a 1-year total return of 15.1%. The stock closed recently at ¥1,230.5, slightly above the consensus analyst price target of ¥1,177, suggesting it may be 4.5% overvalued. Analysts show mixed views, with targets ranging from ¥1,000 to ¥1,500, hinging on expected earnings growth, margin improvements, and risks like rising labor and raw material costs, plus recall expenses. With ¥2.64 trillion in revenue and ¥26.7 billion net income, investors face the decision to buy amid uncertain margin pressure or await clearer signals. Monitoring risks and rewards closely is advised as the stock builds momentum amid market fluctuations.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
Go toTop